Business Context and Reporting Period
Company: Prestige Brands Holdings, Inc. (Prestige)
Filing Type: Form 10-K (Annual Report)
Period Ended: March 31, 2008
Business Overview: Prestige markets, sells, and distributes well-recognized brand name over-the-counter (OTC) healthcare, household cleaning, and personal care products. The company operates in niche segments, utilizing a low-cost operating model that outsources manufacturing and logistics to third-party providers while focusing internal resources on marketing, sales, and product innovation. Major brands include Chloraseptic, Clear Eyes, Comet, Compound W, and Cutex.
Key Financial Metrics
| Metric | Fiscal 2008 | Fiscal 2007 | Fiscal 2006 |
|---|---|---|---|
| Total Revenues | $326.6 million | $318.6 million | $296.7 million |
| Gross Profit | $168.5 million | $165.5 million | $157.2 million |
| Gross Margin | 51.6% | 51.9% | 53.0% |
| Operating Income | $91.4 million | $94.7 million | $83.9 million |
| Net Income | $33.9 million | $36.1 million | $26.3 million |
| Diluted EPS | $0.68 | $0.72 | $0.53 |
| Cash from Operations | $45.0 million | $71.9 million | $53.9 million |
| Total Debt (incl. current) | $411.2 million | $463.4 million | $498.6 million |
| Cash & Equivalents | $6.1 million | $13.8 million | $8.2 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 2.5% to $326.6 million. Excluding the impact of the Wartner acquisition, organic revenue growth was 0.8%.
- OTC Healthcare: Increased 5.1% driven by the Wartner acquisition and the launch of Murine Earigate, offset by declines in Chloraseptic and Little Remedies.
- Household Cleaning: Increased 1.8% primarily due to Comet brand growth, offset by declines in Spic and Span and Chore Boy.
- Personal Care: Declined 12.5% due to lower consumption and lost market share in Cutex and Denorex.
- Profitability: Net income decreased 6.0% to $33.9 million. Gross margin compressed slightly to 51.6% due to unfavorable sales mix, increased promotional allowances, and higher raw material costs.
- Little Remedies Impact: Gross profit was adversely affected by inventory costs associated with the voluntary withdrawal of two medicated pediatric cough and cold products in October 2007.
- Debt Reduction: The company repaid $52.1 million of senior debt using free cash flow, reducing total indebtedness from $463.4 million to $411.2 million.
- Operating Expenses: General and administrative expenses increased $3.0 million, largely due to professional fees related to the OraSure litigation and intellectual property protection for The Doctor's NightGuard.
Guidance, Outlook, Risks, and Unusual Items
- Outlook & Strategy: Management plans to continue investing in advertising and promotion to drive growth in key brands. Future product introductions include Chloraseptic Allergen Block and Little Allergies. The company intends to grow its international business, which represented 4.0% of revenues in 2008.
- Unusual Items:
- Product Withdrawal: In October 2007, the company voluntarily withdrew two Little Remedies pediatric cough and cold products pending FDA review, resulting in a $1.7 million increase in the allowance for returns and lost sales.
- Stock-Based Compensation Reversal: The company reversed $1.1 million of previously recorded stock-based compensation costs in 2008 because performance goals for certain grants were not met.
- Key Risks:
- Customer Concentration: Wal-Mart accounted for approximately 23% of gross sales in 2008. The top five customers accounted for 46% of sales.
- Manufacturing Dependence: All products are manufactured by third parties. Approximately 23% of sales are produced by manufacturers with whom the company has no long-term contracts.
- Intellectual Property Litigation: Ongoing litigation against DenTek regarding The Doctor's NightGuard and a concluded arbitration with OraSure regarding the Wartner brand (resulting in nominal damages).
- Debt Covenants: The company is subject to restrictive covenants regarding leverage, interest coverage, and fixed charge coverage ratios. Failure to comply could result in debt acceleration.
Investor Verification Checklist
- Wal-Mart Dependency: Verify the stability of the relationship with Wal-Mart, which represents nearly a quarter of total sales.
- Little Remedies Reintroduction: Monitor the timeline and regulatory approval for the reintroduction of the withdrawn pediatric cough and cold products.
- Debt Service Capacity: Assess the ability to service $411.2 million in debt given the decline in operating cash flow from $71.9 million (2007) to $45.0 million (2008).
- Personal Care Segment: Evaluate the long-term viability of the Personal Care segment, which has seen consistent revenue declines and margin compression.
- Third-Party Manufacturing: Review the status of contracts with the top 10 manufacturers, particularly those without long-term agreements covering 23% of sales.